daftar pustaka - institutional repository undip (undip...
TRANSCRIPT
63
DAFTAR PUSTAKA
1. World Health Organization. Global status report on noncommunicable diseases
2014. Geneva: World Health Organization; 2014.
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A
comparative risk assessment of burden of disease and injury attributable to 67
risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet.
2012;380(9859):2224–60.
3. World Health Statistics. Causes of death 2008 : data sources and methods.
World Health. 2011;2010(September 2010):1–28.
4. Cardiovascular disease risk factors - Hypertension [Internet]. World Heart
Federation. [cited 2016 Jan 17]. Available from: http://www.world-heart-
federation.org/cardiovascular-health/cardiovascular-disease-risk-
factors/hypertension/
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N
Engl J Med. 2005;352(16):1685–95.
6. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et
al. General cardiovascular risk profile for use in primary care: the Framingham
Heart Study. Circulation. 2008 Feb 12;117(6):743–53.
7. Bouhanick B, Barbosa SLS, Marre M. Hypertension and diabetes. Arch Mal
Coeur Vaiss. 2000;93(11, S):1429–34.
8. IDF Diabetes ATLAS. 7th ed. Brussels: International Diabetes Federation;
2015. 12-7 p.
9. WHO | Diabetes [Internet]. World Health Organization; [cited 2015 Nov 23].
Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
10. American Heart Association. Cardiovascular Disease & Diabetes [Internet].
[cited 2015 Nov 23]. Available from:
http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/
Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.VlJnCtLhDIV
63
64
11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al.
European Guidelines on Cardiovascular Disease Prevention in Clinical
Practice. The Fifth Joint Task Force of the European Society of Cardiology and
Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur
Heart J. 2012;33(13):1635–701.
12. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood.
Korean Circ J. 2010;40(1):1–9.
13. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr.
SK. Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study
Collaborative Research Group. N Engl J Med. 1999;340(1):14–22.
14. Gómez-Marcos MA, Recio-Rodríguez JI, Rodríguez-Sánchez E, Patino-
Alonso MC, Magallón-Botaya R, Martínez-Vizcaino V, et al. Carotid Intima-
Media Thickness in Diabetics and Hypertensive Patients. Rev Española Cardiol
(English Ed. Elsevier; 2011 Jul 1;64(7):622–5.
15. Alatab S, Fakhrzadeh H, Sharifi F, Mostashfi A, Mirarefin M, Badamchizadeh
Z, et al. Impact of hypertension on various markers of subclinical
atherosclerosis in early type 2 diabetes. J Diabetes Metab Disord.
2014;13(1):24.
16. Marieb EN, Hoehn K. Human Anatomy & Physiology. 7th ed. San Francisco:
Benjamin Cummings; 2006.
17. Mescher AL. Junqueiras’s Basic Histology: Text and Atlas. 13th ed. New
York: McGraw-Hill Education; 2013. 217-24 p.
18. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 9th ed.
Philadelphia: Elsevier Saunders; 2013. 335-43 p.
19. Libby P. The Pathogenesis, Prevention, and Treatment of Atherosclerosis. In:
Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors.
Harrison’s Principles of Internal Medicine. 19th ed. McGraw-Hill Education;
2015. p. 291e1–10.
20. Steinl DC, Kaufmann BA. Ultrasound imaging for risk assessment in
atherosclerosis. Int J Mol Sci. Multidisciplinary Digital Publishing Institute;
65
2015 Jan 29;16(5):9749–69.
21. Sherwood L. Fisiologi Manusia: dari Sel ke Sistem. 6th ed. Jakarta: Penerbit
Buku Kedokteran EGC; 2012.
22. Finn A V, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of
vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010 Jul
1;30(7):1282–92.
23. Antman EM, Loscalzo J. Ischemic Heart Disease. In: Kasper DL, Hauser SL,
Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of
Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 1578–92.
24. Coronary Artery Disease [Internet]. National Library of Medicine; [cited 2016
Jan 9]. Available from:
https://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html
25. Coronary Artery Disease - Coronary Heart Disease [Internet]. [cited 2016 Jan
9]. Available from:
http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/
Coronary-Artery-Disease---Coronary-Heart-
Disease_UCM_436416_Article.jsp#.VpENI7aLTIU
26. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, Idrus A,
Sudoyo A w, Simadibrata K. M, Setiyohadi B, Syam AF, editors. Buku Ajar
Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 1518–28.
27. Ropper AH, Samuels MA. Cerebrovascular Disease. In: Adams and Victor’s
Principle of Neurology. 9th ed. New York: McGraw-Hill; 2009. p. 746.
28. Ischemic Stroke | Internet Stroke Center [Internet]. [cited 2016 Jan 17].
Available from: http://www.strokecenter.org/patients/about-stroke/ischemic-
stroke/
29. History of the Framingham Heart Study [Internet]. [cited 2016 Jan 8].
Available from: https://www.framinghamheartstudy.org/about-fhs/history.php
30. Hackam DG, Anand SS. Emerging Risk Factors for Atherosclerotic Vascular
Disease: A Critical Review of the Evidenc. JAMA. 2003;290(7):932–40.
31. Strom JB, Libby P. Atherosclerosis. In: Lily L, editor. Pathophysiology of
Heart Disease. 5th ed. Walter Kluwer; 2011. p. 113–4.
66
32. Adi PR. Pencegahan dan Penatalaksanaan Aterosklerosis. In: Setiati S, Alwi I,
Sudoyo AW, Setiyohadi B, Sumandibrata K M, Syam AF, editors. Buku Ajar
Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 1427–37.
33. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Luther T, Hunninghake
DB, et al. Implications of Recent Clinical Trials for the Natinal Cholesterol
Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb
Vasc Biol. 2004;24:e149–61.
34. European Society of Hypertension - European Society of Cardiology
Guidelines Committee. European Society of Hypertension - European Society
of Cardiology Guidelines for The Management of Arterial Hypertension. J
Hypertens. 2003;21(1011):53.
35. Chobanian A V., Bakris GL, Black HR, Cushman WC, Green L a., Izzo JL, et
al. Seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Hypertension.
2003;42(6):1206–52.
36. Kementrian Kesehatan RI. Infodatin Hipertensi. Jakarta; 2014.
37. Tedjasukmana P. Tata Laksana Hipertensi. Cdk-192. 2012;39(4):251–5.
38. Alexander RW. Hypertension and the Pathogenesis of Atherosclerosis :
Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New
Perspective. Hypertension. Lippincott Williams & Wilkins; 1995 Feb
1;25(2):155–61.
39. Purnamasari D. Diagnosis dan klasifikasi diabetes mellitus. In: Setiati S, Alwi
I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar
Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 2325–9.
40. Powers AC. Diabetes Mellitus: Complications. In: Kasper DL, Hauser SL,
Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of
Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 2422–30.
41. Pedicino D, Giglio AF, Galiffa VA, Trotta F, Liuzzo G. Type 2 Diabetes,
Immunity and Cardiovascular Risk: A Complex Relationship. In: Oguntibeju
O, editor. Pathophysiology and Complications of Diabetes Mellitus. InTech;
2012.
67
42. Rask-madsen C, King GL. Review Vascular Complications of Diabetes :
Mechanisms of Injury and Protective Factors. Cell Metab. Elsevier Inc.;
2012;17(1):20–33.
43. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in Type 2 Diabetes :
Prevalence , Pathophysiology , and Management. Drugs. 2013;73:327–39.
44. Fodor G. Clinical Evidence Handbook: Primary Prevention of CVD: Treating
Dyslipidemia. Am Fam Physician. 2011;83(10):1207–8.
45. Adam JMF. Dislipidemia. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata K.
M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed.
Jakarta: InternaPublishing; 2014. p. 2551–60.
46. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA. 2001 May 16;285(19):2486–97.
47. Ballantyne CM, O’Keefe Jr. JH, Gotto Jr. AM. Dyslipidemia &
Atherosclerosis Essentials 2009. 4th ed. Jones & Bartlett Publishers; 2009.
48. Centers for Disease Control and Prevention, National Center for Chronic
Disease Prevention and Health Promotion, Office on Smoking and Health.
Cardiovascular Diseases. In: How Tobacco Smoke Causes Disease: The
Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of
the Surgeon General. Centers for Disease Control and Prevention (US); 2010.
49. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an
independent risk factor for cardiovascular disease: a 26- year follow-up of
participants in the Framingham Heart Study. Circulation. 1983 May
1;67(5):968–77.
50. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic
insights. Can J Cardiol. 2015 Feb;31(2):177–83.
51. Bowles DK, Laughlin MH. Mechanism of beneficial effects of physical
activity on atherosclerosis and coronary heart disease. J Appl Physiol.
2011;111(21):308–10.
52. Gray HH, Dawkins KD, Simpson IA, Morgan JM. Lecture Notes: Kardiologi.
68
5th ed. Wiley; 2008.
53. Vitale C, Miceli M, Rosano GMC. Gender-specific characteristics of
atherosclerosis in menopausal women: risk factors, clinical course and
strategies for prevention. Climacteric. 2007 Oct;10 Suppl 2:16–20.
54. Nasir K, Michos ED, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, et
al. Coronary artery calcification and family history of premature coronary heart
disease: sibling history is more strongly associated than parental history.
Circulation. 2004 Oct 12;110(15):2150–6.
55. Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, et al.
Family history of premature coronary heart disease and coronary artery
calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation.
2007 Aug 7;116(6):619–26.
56. Michos ED, Vasamreddy CR, Becker DM, Yanek LR, Moy TF, Fishman EK,
et al. Women with a low Framingham risk score and a family history of
premature coronary heart disease have a high prevalence of subclinical
coronary atherosclerosis. Am Hear J. 2005 Dec;150(6):1276–81.
57. Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk
factors for atherosclerosis and patient risk assessment. Circulation. 2004 Jun
15;109(23 Suppl 1):III15–9.
58. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial
thickness of the arterial wall: a direct measurement with ultrasound imaging.
Circulation. 1986. p. 1399–406.
59. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F, Bots
ML, et al. Measurement of carotid intima–media thickness to assess
progression and regression of atherosclerosis. Nature. 2008;5(5):280–8.
60. Simova I. Intima-media thickness: Appropriate evaluation and proper
measurement, described. E-journal Cardiol Pract. 2015;13.
61. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media
thickness. Eur Heart J. 2010;31(14):1682–9.
62. Srámek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound
assessment of atherosclerotic vessel wall changes: reproducibility of intima-
69
media thickness measurements in carotid and femoral arteries. Invest Radiol.
2000 Dec;35(12):699–706.
63. Touboul P-J, Labreuche J, Vicaut E, Belliard J-P, Cohen S, Kownator S, et al.
Country-based reference values and impact of cardiovascular risk factors on
carotid intima-media thickness in a French population: the “Paroi Artérielle et
Risque Cardio-Vasculaire” (PARC) Study. Cerebrovasc Dis. 2009
Jan;27(4):361–7.
64. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use
of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate
Cardiovascular Disease Risk: A Consensus Statement from the American
Society of Echocardiography Carotid Intima-Media Thickness Task Force
Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr.
2008;21(2):93–111.
65. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B??hm M, et al.
2013 ESH/ESC guidelines for the management of arterial hypertension: The
Task Force for the management of arterial hypertension of the European
Society of Hypertension (ESH) and of the European Society of Cardiology
(ESC). Eur Heart J. 2013;34(28):2159–219.
66. Folkow B. Cardiovascular structural adaptation; its role in the initiation and
maintenance of primary hypertension. Clin Sci Mol Med Suppl. 1978;4:3s –
22s.
67. Gaballa MA, Jacob CT, Raya TE, Liu J, Simon B, Goldman S. Large Artery
Remodeling During Aging : Biaxial Passive and Active Stiffness.
Hypertension. 1998 Sep 1;32(3):437–43.
68. Tanaka H, Dinenno FA, Monahan KD, Desouza CA, Seals DR. Carotid artery
wall hypertrophy with age is related to local systolic blood pressure in healthy
men. Arter Thromb Vasc Biol. 2001;21(1):82–7.
69. Department of Chronic Diseases and Health Promotion. Global Physical
Activity Questionnaire. Geneva: World Health Organization; 2012. 1-8 p.
70. Kusumawardani RP. Kontribusi hipertensi terhadap aterosklerosis arteri
karotis interna pada pasien pasca stroke iskemik. Universitas Diponegoro;
70
2011.
71. Katakami N, Yamasaki Y, Ayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa
M, et al. Metformin or gliclazide, rather than glibenclamide, attenuate
progression of carotid intima-media thickness in subjects with type 2 diabetes.
Diabetologia. 2004;47:1906–13.
72. Stettler C, Allemann S, Ju P. Glycemic control and macrovascular disease in
types 1 and 2 diabetes mellitus : Meta-analysis of randomized trials. Am Hear
J. 2006;152(1):27–38.
73. Sutton-tyrrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH.
Carotid Atherosclerosis in Premenopausal and Postmenopausal Women and Its
Association With Risk Factors Measured After Menopause. Stroke.
1998;29(6):1116–21.
74. Im TS, Chun EJ, Lee MS, Adla T, Kim JA, Choi S Il. Grade-response
relationship between blood pressure and severity of coronary atherosclerosis in
asymptomatic adults : assessment with coronary CT angiography. Int J
Cardiovasc Imaging. 2014;30:105–12.
75. Darmawan A, Tugasworo D, Pemayun TGD. Hiperglikemia dan
Aterosklerosis Arteri Karotis Interna pada Penderita Pasca Stroke Iskemik. M
Med Indones. 2011;45(1):1–7.
76. Fromm A, Haaland ØA, Naess H, Thomassen L, Waje-andreassen U. Risk
factors and their impact on carotid intima-media thickness in young and
middle-aged ischemic stroke patients and controls : The Norwegian Stroke in
the Young Study. BMC. 2014;7(176):1–8.
77. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of Comorbid
Hypertension and Dyslipidemia and Associated Cardiovascular Disease. Am J
Manag Care. 2004;10(12):926–32.
78. Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of
diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig.
2014;5(5):507–12.
79. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature.
2009;5(3):150–9.
71
Lampiran 1.
PROSEDUR PENGUKURAN CIMT
1) Memposisikan pemeriksa dan pasien senyaman mungkin dimana pasien
terbaring pada tempat tidur dan pemeriksa duduk di samping kanan pasien.
2) Mengekstensikan leher dan memposisikan kepala pasien menoleh
kontralateral terhadap sisi leher yang akan diperiksa, kemudian mengoleskan
gel pada leher atau pada transduser.
3) Melakukan skrinning arteri karotis komunis menggunakan transduser dengan
orientasi transversal, dari proksimal hingga distal, sambil melihat layar
monitor hingga menemukan bulbus karotikus.
4) Memposisikan orientasi transduser menjadi longitudinal pada sisi lateral
arteri karotis kemudian merekam pencitraan pada monitor dalam bentuk
gambar diam.
5) Melakukan pengukuran CIMT pada dinding jauh pembuluh darah
menggunakan perangkat lunak pada alat.
6) Melakukan pemeriksaan dan pengukuran CIMT pada sisi leher yang lain
dengan cara yang sama.
7) Mengambil nilai rata – rata CIMT.
72
Lampiran 2. Ethical clearance
73
Lampiran 3. Surat izin melaksanakan penelitian
74
75
Lampiran 4. Informed cosent
76
77
Lampiran 5. Kuesioner
DAFTAR TILIK PENELUSURAN REKAM MEDIK DAN
WAWANCARA
No. CM :
Nama :
Jenis kelamin : Laki-laki Perempuan
Umur :
Pekerjaan :
Alamat :
No. HP :
Tinggi badan : _____cm Berat badan : _____ kg BMI : _____ kg/m2
Kontrol teratur/tidak : Ya Tidak
Status merokok : Ya Tidak
Data
Hipertensi
Tekanan darah
terakhir
Lama hipertensi Obat yang diminum
Data DM
Status DM : Ya Tidak
Anamnesis 3P + kadar GDS
Anamnesis 3P + kadar GDP
Lainnya (diagnosis dokter, mendapat terapi DM)
mg/dl
mg/dl
78
Kadar gula darah terakhir : GDP______mg/dl; GDS______ mg/dl
2PP ______mg/dl
Kadar HbA1c :
Lama DM :
Obat yang diminum :
Data dislipidemia
Status dislipidemia : Ya Tidak
Kadar kolesterol total : ________ mg/dl (dislipidemia: ≥240 mg/dl)
Kadar kolesterol LDL : ________ mg/dl (dislipidemia: ≥160 mg/dl)
Kadar kolesterol HDL : ________ mg/dl (dislipidemia: <40 mg/dl)
Kadar trigliserida : ________ mg/dl (dislipidemia: ≥200 mg/dl)
Lama dislipidemia :
Obat yang diminum :
Komplikasi/ penyakit lainnya
79
GLOBAL PHYSICAL ACTIVITY QUESTIONNAIRE (GPAQ)
Jenis Aktivitas Contoh Aktivitas
Aktivitas ringan Duduk, berdiri, mencuci piring, memasak, menyetrika, bermain
musik, menonton tv, mengemudikan kendaraan, berjalan perlahan
Aktivitas sedang Menyapu, mengepel, mencuci mobil, menanam tanaman, memanen
tanaman, menimba air, bersepeda pergi pulang beraktivitas,
Aktivitas berat Membawa barang berat, berkebun (menggali), bersepeda (16-
22km/jam), bermain sepak bola,
Olahraga sedang
Aerobik low-impact, berkuda, voli, berjalan sedang dan cepat,
bowling, golf, tenis meja, berenang, bersepeda, jogging, menari, tai
chi, yoga, kriket
Olahraga berat Sepak bola, basket, gym angkat berat, berlari, rugby, tennis, aerobik
high-impact, aerobik air, menari ballet, berenang cepat
Aktivitas fisik
Kode Pertanyaan Jawaban Aktivitas saat belajar / bekerja (Aktivitas termasuk kegiatan belajar, latihan, aktivitas rumah tangga, dll
P1
Apakah aktivitas sehari- hari Anda, termasuk
aktivitas berat (seperti membawa beban berat,
menggali atau pekerjaan konstruksi lain ) ?
1. Ya
2. Tidak (langsung ke P4)
P2 Berapa hari dalam seminggu Anda
melakukan aktivitas berat?
hari
P3 Berapa lama dalam sehari biasanya Anda
melakukan aktivitas berat?
Jam menit
P4
Apakah aktivitas sehari-hari Anda termasuk
aktivitas sedang yang menyebabkan
peningkatan nafas dan denyut nadi, seperti
mengangkat beban ringan dan jalan sedang
(minimal 10 menit secara kontinyu) ?
1. Ya
2. Tidak (langsung ke P7)
P5 Berapa hari dalam seminggu Anda
melakukan aktivitas sedang?
hari
P6 Berapa lama dalam sehari biasanya Anda
melakukan aktivitas sedang ?
Jam menit
80
Perjalanan ke dan dari tempat aktivitas
Perjalanan ke tempat aktivtias, berbelanja, beribadah diluar, dll)
P7
Apakah Anda berjalan kaki atau bersepeda
untuk pergi ke suatu tempat minimal 10 menit
kontinyu ?
1. Ya
2. Tidak (langsung ke P10)
P8 Berapa hari dalam seminggu Anda
berjalan kaki atau bersepeda untuk pergi ke
suatu tempat?
hari
P9 Berapa lama dalam sehari biasanya Anda
berjalan kaki atau bersepeda untuk pergi ke
suatu tempat?
Jam menit
Aktivitas rekreasi (Olaraga, fitnes, dan rekreasi lainnya)
P10
Apakah Anda melakukan olahraga, fitnes, atau rekreasi yang berat seperti lari, sepak bola atau rekreasi lainnya yang mengakibatkan peningkatan nafas dan denyut nadi secara besar (minimal dalam 10 menit secara kontinyu)?
1. Ya
2. Tidak (langsung ke P13)
P11
Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat?
hari
P12
Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat?
Jam menit
P13
Apakah Anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang seperti berjalan
cepat, bersepeda, berenang, voli yang
mengakibatkan peningkatan nafas dan denyut nadi
(minimal dalam 10 menit secara kontinyu)?
1. Ya
2. Tidak (langsung ke
P16)
P14
Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitnes, atau rekreasi lainnya yang tergolong sedang?
hari
P15
Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang?
Jam menit
Aktivitas menetap (Sedentary behavior) Aktivitaas yang tidak memerlukan banyak gerak seperti duduk saat bekerja, duduk saat di kendaraan, menonton televisi, atau berbaring, KECUALI tidur
P16 Berapa lama Anda duduk atau berbaring dalam sehari?
Jam menit
81
Lampiran 6. Tabulasi Data Subjek Penelitian
No Nama Sex Usia
(tahun)
BMI
(kg/m2)
Status
obesitas
Tekanan darah
terakhir
Lama
HT
(tahun)
1 RSN L 52 25.8 Ya Hipertensi derajat 1 2
2 KHSK P 55 25.8 Ya HT terkontrol 15
3 MZNR L 50 23.8 Tidak Hipertensi derajat 1 2
4 SRSP P 55 19.6 Tidak HT terkontrol 5
5 STM P 58 22.0 Tidak Hipertensi derajat 1 1
6 DJMN P 54 25.7 Ya Hipertensi derajat 1 10
7 KHST P 33 17.7 Tidak Hipertensi derajat 1 4
8 SPD L 59 25.0 Ya Hipertensi derajat 1 10
9 FDLM P 56 25.0 Ya Hipertensi derajat 1 <1
10 DYSW P 58 23.0 Tidak Hipertensi derajat 2 21
11 JMLN P 51 27.3 Ya Hipertensi derajat 2 <1
12 AMRL L 46 24.3 Tidak Hipertensi derajat 2 9
13 AGST L 49 20.1 Tidak Hipertensi derajat 2 2
14 YSPE L 32 22.5 Tidak Hipertensi derajat 2 2
15 SHRT L 47 25.4 Ya HT terkontrol <1
16 NRHS L 30 28.3 Ya Hipertensi derajat 1 <1
17 SRWH P 46 20.0 Tidak Hipertensi derajat 1 17
18 JPRY L 58 27.3 Ya Hipertensi derajat 2 5
19 SMTW L 43 22.0 Tidak Hipertensi derajat 1 <1
20 MSYD P 59 25.4 Ya Hipertensi derajat 1 <1
21 BDLS P 58 32.9 Ya HT terkontrol 10
22 HRT P 51 28.8 Ya HT terkontrol 1
23 SRRH P 51 28.5 Ya HT terkontrol 3
24 LDNR P 36 25.5 Ya Hipertensi derajat 2 2
25 BSTM L 58 18.6 Tidak Hipertensi derajat 1 13
26 WJST P 48 18.0 Tidak HT terkontrol 2
27 STRN L 48 20.6 Tidak Hipertensi derajat 1 <1
28 UMRH P 37 20.8 Tidak HT terkontrol 1
29 SDD L 59 25.21 Ya HT terkontrol 2
30 ANDP L 55 27.68 Ya HT terkontrol <1
31 IDSYR P 59 27.94 Ya Hipertensi derajat 1 26
32 STRS L 45 24.34 Tidak Hipertensi derajat 2 <1
82
No Status
DM
Lama
DM
(tahun)
Status
dislipidemia
Tingkat
aktivitas
fisik
CIMT
(mm)
Penyakit
Aterosklerosis
1 Ya 1 Ya rendah 2.22
2 Tidak 0 Tidak rendah 0.67
3 Tidak 0 Tidak rendah 0.35
4 Ya 5 Ya rendah 0.80
5 Tidak 0 Ya tinggi 0.57 PJK
6 Tidak 0 Ya rendah 1.64 PJK
7 Tidak 0 Ya rendah 0.55
8 Ya 9 Ya rendah 0.76 SNH
9 Tidak 0 Tidak rendah 0.74
10 Ya 7 Ya rendah 1.01 PJK
11 Ya 7 Ya rendah 0.51
12 Tidak 0 Ya rendah 0.70
13 Tidak 0 Ya sedang 0.72 PJK, SNH
14 Tidak 0 Tidak rendah 0.84
15 Tidak 0 Ya tinggi 0.79 PJK
16 Ya 17 Ya rendah 0.56
17 Ya <1 Tidak rendah 0.59
18 Tidak 0 Ya rendah 1.20 SNH
19 Tidak 0 Ya rendah 0.62 PJK, SNH
20 Tidak 0 Tidak sedang 0.35
21 Ya 10 Ya rendah 1.15 PJK
22 Ya 1 Ya sedang 0.93
23 Ya 3 Ya sedang 0.65
24 Tidak 0 Ya sedang 1.03
25 Tidak 0 Tidak rendah 0.50 PJK, SNH
26 Tidak 0 Tidak sedang 0.77
27 Ya 6 Ya sedang 1.14 PJK
28 Ya <1 Tidak rendah 0.6
29 Ya 12 Tidak sedang 0.7
30 Ya 3 Ya rendah 1.17 PJK
31 Ya 26 Ya rendah 0.91
32 Ya 5 Ya tinggi 1.43
83
Lampiran 7. Hasil Analisis Statistik
Frequencies
Frequency Table
Jenis kelamin
15 46.9 46.9 46.9
17 53.1 53.1 100.0
32 100.0 100.0
Laki-laki
Perempuan
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Usia
5 15.6 15.6 15.6
8 25.0 25.0 40.6
19 59.4 59.4 100.0
32 100.0 100.0
20-39
40-49
50-59
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Obesitas
17 53.1 53.1 53.1
15 46.9 46.9 100.0
32 100.0 100.0
Ya
Tidak
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
DM
16 50.0 50.0 50.0
16 50.0 50.0 100.0
32 100.0 100.0
Ya
Tidak
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Dislipidemia
22 68.8 68.8 68.8
10 31.3 31.3 100.0
32 100.0 100.0
Ya
Tidak
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Tingkat aktivitas fisik
21 65.6 65.6 65.6
8 25.0 25.0 90.6
3 9.4 9.4 100.0
32 100.0 100.0
Rendah
Sedang
Tinggi
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
84
Crosstabs
Jenis kelamin * DM
Usia * DM
Crosstab
7 8 15
7.5 7.5 15.0
43.8% 50.0% 46.9%
9 8 17
8.5 8.5 17.0
56.3% 50.0% 53.1%
16 16 32
16.0 16.0 32.0
100.0% 100.0% 100.0%
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Laki-laki
Perempuan
Jenis kelamin
Total
Ya Tidak
DM
Total
Chi-Square Tests
.125b 1 .723
.000 1 1.000
.126 1 .723
1.000 .500
.122 1 .727
32
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea.
0 cells (.0%) have expected count less than 5. The minimum expected count is 7.
50.
b.
Crosstab
2 3 5
2.5 2.5 5.0
12.5% 18.8% 15.6%
3 5 8
4.0 4.0 8.0
18.8% 31.3% 25.0%
11 8 19
9.5 9.5 19.0
68.8% 50.0% 59.4%
16 16 32
16.0 16.0 32.0
100.0% 100.0% 100.0%
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
20-39
40-49
50-59
Usia
Total
Ya Tidak
DM
Total
85
Mann-Whitney Test Ranks
DM N Mean Rank Sum of Ranks
Usia Ya 16 17.97 287.50
Tidak 16 15.03 240.50
Total 32
Test Statisticsa
Usia
Mann-Whitney U 104.500
Wilcoxon W 240.500
Z -1.008
Asymp. Sig. (2-tailed) .313
Exact Sig. [2*(1-tailed Sig.)] .381b
a. Grouping Variable: DM
b. Not corrected for ties.
Obesitas * DM
Chi-Square Tests
1.174a 2 .556
1.182 2 .554
.867 1 .352
32
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
4 cells (66.7%) have expected count less than 5. The
minimum expected count is 2.50.
a.
Crosstab
10 7 17
8.5 8.5 17.0
62.5% 43.8% 53.1%
6 9 15
7.5 7.5 15.0
37.5% 56.3% 46.9%
16 16 32
16.0 16.0 32.0
100.0% 100.0% 100.0%
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Ya
Tidak
Obesitas
Total
Ya Tidak
DM
Total
Chi-Square Tests
1.129b 1 .288
.502 1 .479
1.136 1 .286
.479 .240
1.094 1 .296
32
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea.
0 cells (.0%) have expected count less than 5. The minimum expected count is 7.
50.
b.
86
Dislipidemia * DM
Tingkat aktivitas fisik * DM
Crosstab
13 9 22
11.0 11.0 22.0
81.3% 56.3% 68.8%
3 7 10
5.0 5.0 10.0
18.8% 43.8% 31.3%
16 16 32
16.0 16.0 32.0
100.0% 100.0% 100.0%
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Ya
Tidak
Dislipidemia
Total
Ya Tidak
DM
Total
Chi-Square Tests
2.327b 1 .127
1.309 1 .253
2.377 1 .123
.252 .126
2.255 1 .133
32
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea.
0 cells (.0%) have expected count less than 5. The minimum expected count is 5.
00.
b.
Crosstab
11 10 21
10.5 10.5 21.0
68.8% 62.5% 65.6%
4 4 8
4.0 4.0 8.0
25.0% 25.0% 25.0%
1 2 3
1.5 1.5 3.0
6.3% 12.5% 9.4%
16 16 32
16.0 16.0 32.0
100.0% 100.0% 100.0%
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Count
Expected Count
% within DM
Rendah
Sedang
Tinggi
Tingkat
aktivitas
fisik
Total
Ya Tidak
DM
Total
Chi-Square Tests
.381a 2 .827
.387 2 .824
.279 1 .597
32
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
4 cells (66.7%) have expected count less than 5. The
minimum expected count is 1.50.
a.
87
Mann-Whitney Test Ranks
DM N Mean Rank Sum of Ranks
Tingkat aktivitas fisik Ya 16 15.88 254.00
Tidak 16 17.13 274.00
Total 32
Test Statisticsa
Tingkat aktivitas
fisik
Mann-Whitney U 118.000
Wilcoxon W 254.000
Z -.450
Asymp. Sig. (2-tailed) .653
Exact Sig. [2*(1-tailed Sig.)] .724b
a. Grouping Variable: DM
b. Not corrected for ties.
Riwayat merokok*DM Riwayat merokok * DM Crosstabulation
DM
Total Ya Tidak
Riwayat merokok Ya Count 5 8 13
% within Riwayat merokok 38.5% 61.5% 100.0%
Tidak Count 11 8 19
% within Riwayat merokok 57.9% 42.1% 100.0%
Total Count 16 16 32
% within Riwayat merokok 50.0% 50.0% 100.0%
Chi-Square Tests
Value df
Asymptotic Significance
(2-sided) Exact Sig. (2-
sided) Exact Sig. (1-
sided)
Pearson Chi-Square 1.166a 1 .280
Continuity Correctionb .518 1 .472
Likelihood Ratio 1.174 1 .279 Fisher's Exact Test .473 .236
Linear-by-Linear Association
1.130 1 .288
N of Valid Cases 32 a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.50.
b. Computed only for a 2x2 table
Derajat hipertensi*DM Derajat hipertensi * DM Crosstabulation
DM
Total Ya Tidak
Derajat hipertensi HT derajat 2 Count 3 5 8
% within Derajat hipertensi 37.5% 62.5% 100.0%
HT derajat 1 Count 6 8 14
% within Derajat hipertensi 42.9% 57.1% 100.0%
88
HT terkontrol Count 7 3 10
% within Derajat hipertensi 70.0% 30.0% 100.0%
Total Count 16 16 32
% within Derajat hipertensi 50.0% 50.0% 100.0%
Chi-Square Tests
Value Df
Asymptotic Significance (2-
sided)
Pearson Chi-Square 2.386a 2 .303
Likelihood Ratio 2.438 2 .296 N of Valid Cases 32 a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 4.00.
Mann-Whitney Test Ranks
DM N Mean Rank Sum of Ranks
Derajat hipertensi Ya 16 18.69 299.00
Tidak 16 14.31 229.00
Total 32
Test Statisticsa
Derajat hipertensi
Mann-Whitney U 93.000
Wilcoxon W 229.000
Z -1.413
Asymp. Sig. (2-tailed) .158
Exact Sig. [2*(1-tailed Sig.)] .196b
a. Grouping Variable: DM
b. Not corrected for ties.
Lama hipertensi*DM Lama hipertensi * DM Crosstabulation
DM
Total Ya Tidak
Lama hipertensi <5 tahun Count 10 11 21
% within Lama hipertensi 47.6% 52.4% 100.0%
5-10 tahun Count 3 3 6
% within Lama hipertensi 50.0% 50.0% 100.0%
>10 tahun Count 3 2 5
% within Lama hipertensi 60.0% 40.0% 100.0%
Total Count 16 16 32
% within Lama hipertensi 50.0% 50.0% 100.0%
Chi-Square Tests
Value df
Asymptotic
Significance (2-
sided)
Pearson Chi-Square .248a 2 .884
Likelihood Ratio .249 2 .883
Linear-by-Linear Association .215 1 .643
N of Valid Cases 32
a. 4 cells (66.7%) have
expected count less than
5. The minimum
expected count is 2.50.
89
Mann-Whitney Test Ranks
DM N Mean Rank Sum of Ranks
Lama hipertensi Ya 16 17.09 273.50
Tidak 16 15.91 254.50
Total 32
Test Statisticsa
Lama hipertensi
Mann-Whitney U 118.500
Wilcoxon W 254.500
Z -.426
Asymp. Sig. (2-tailed) .670
Exact Sig. [2*(1-tailed Sig.)] .724b
a. Grouping Variable: DM
b. Not corrected for ties.
Explore Jenis Kelamin-CIMT (DM - Non DM)
Case Summaries
CIMT
DM Jenis kelamin N Mean Std. Deviation Median Minimum Maximum
Ya Laki-laki 7 1.1400 .56654 1.1400 .56 2.22
Perempuan 9 .7944 .21967 .8000 .51 1.15
Total 16 .9456 .43066 .8550 .51 2.22
Tidak Laki-laki 8 .7150 .25219 .7100 .35 1.20
Perempuan 8 .7900 .39587 .7050 .35 1.64
Total 16 .7525 .32298 .7100 .35 1.64
Total Laki-laki 15 .9133 .46639 .7600 .35 2.22
Perempuan 17 .7924 .30446 .7400 .35 1.64
Total 32 .8491 .38709 .7500 .35 2.22
Explore Usia-CIMT (DM – Non DM)
Case Summaries
CIMT
DM Usia N Mean Std. Deviation Median Minimum Maximum
Ya 20-39 2 .5800 .02828 .5800 .56 .60
40-49 3 1.0533 .42665 1.1400 .59 1.43
50-59 11 .9827 .45824 .9100 .51 2.22
Total 16 .9456 .43066 .8550 .51 2.22
Tidak 20-39 3 .8067 .24173 .8400 .55 1.03
40-49 5 .7200 .06671 .7200 .62 .79
50-59 8 .7525 .44975 .6200 .35 1.64
Total 16 .7525 .32298 .7100 .35 1.64
Total 20-39 5 .7160 .21173 .6000 .55 1.03
40-49 8 .8450 .29037 .7450 .59 1.43
50-59 19 .8858 .45712 .7600 .35 2.22
Total 32 .8491 .38709 .7500 .35 2.22
90
Explore Obesitas-CIMT (DM)
Case Summaries
CIMT DM Obesitas N Mean Std. Deviation Median Minimum Maximum
Ya Ya 10 .9560 .49858 .8350 .51 2.22
Tidak 6 .9283 .32921 .9050 .59 1.43
Total 16 .9456 .43066 .8550 .51 2.22
Tidak Ya 7 .9171 .41744 .7900 .35 1.64
Tidak 9 .6244 .15076 .6200 .35 .84
Total 16 .7525 .32298 .7100 .35 1.64
Total Ya 17 .9400 .45339 .7900 .35 2.22
Tidak 15 .7460 .27466 .7000 .35 1.43
Total 32 .8491 .38709 .7500 .35 2.22
Explore Dislipidemia-CIMT (DM – Non DM)
Case Summaries
CIMT
DM Dislipidemia N Mean Std. Deviation Median Minimum Maximum
Ya Ya 13 1.0185 .44784 .9300 .51 2.22
Tidak 3 .6300 .06083 .6000 .59 .70
Total 16 .9456 .43066 .8550 .51 2.22
Tidak Ya 9 .8689 .36057 .7200 .55 1.64
Tidak 7 .6029 .20246 .6700 .35 .84
Total 16 .7525 .32298 .7100 .35 1.64
Total Ya 22 .9573 .41207 .8550 .51 2.22
Tidak 10 .6110 .16829 .6350 .35 .84
Total 32 .8491 .38709 .7500 .35 2.22
Explore Tingkat aktivitas fisik-CIMT (DM – Non DM)
Case Summaries
CIMT
DM
Tingkat aktivitas
fisik N Mean
Std.
Deviation Median Minimum Maximum
Ya Rendah 11 .9345 .48583 .8000 .51 2.22
Sedang 4 .8550 .22576 .8150 .65 1.14
Tinggi 1 1.4300 . 1.4300 1.43 1.43
Total 16 .9456 .43066 .8550 .51 2.22
Tidak Rendah 10 .7810 .37734 .6850 .35 1.64
Sedang 4 .7175 .28016 .7450 .35 1.03
Tinggi 2 .6800 .15556 .6800 .57 .79
Total 16 .7525 .32298 .7100 .35 1.64
Total Rendah 21 .8614 .43389 .7400 .35 2.22
Sedang 8 .7863 .24675 .7450 .35 1.14
Tinggi 3 .9300 .44677 .7900 .57 1.43
Total 32 .8491 .38709 .7500 .35 2.22
91
Explore
Riwayat merokok-CIMT (DM-Non DM)
Case Summaries
CIMT
DM Riwayat merokok N Mean Std. Deviation Median Minimum Maximum
Ya Ya 5 1.3040 .60277 1.1700 .56 2.22
Tidak 11 .7827 .19865 .7600 .51 1.15
Total 16 .9456 .43066 .8550 .51 2.22
Tidak Ya 8 .7150 .25219 .7100 .35 1.20
Tidak 8 .7900 .39587 .7050 .35 1.64
Total 16 .7525 .32298 .7100 .35 1.64
Total Ya 13 .9415 .49716 .7900 .35 2.22
Tidak 19 .7858 .28789 .7400 .35 1.64
Total 32 .8491 .38709 .7500 .35 2.22
Explore DM-CIMT
Case Summaries
CIMT
16 .9456 .43066 .8550 .51 2.22
16 .7525 .32298 .7100 .35 1.64
32 .8491 .38709 .7500 .35 2.22
DM
Ya
Tidak
Total
N Mean Std. Deviation Median Minimum Maximum
Tests of Normality
.828 16 .007
.880 16 .038
DM
Ya
Tidak
CIMT
Statistic df Sig.
Shapiro-Wilk
Lilliefors Significance Correctiona.
92
NPar Tests Mann-Whitney Test
Jenis kelamin (Keseluruhan) Explore
Tests of Normality
Jenis kelamin
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT Laki-laki .229 15 .033 .850 15 .017
Perempuan .137 17 .200* .908 17 .092
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
NPar Tests Mann-Whitney Test
Ranks
Jenis kelamin N Mean Rank Sum of Ranks
CIMT Laki-laki 15 17.63 264.50
Perempuan 17 15.50 263.50
Total 32
Ranks
16 18.78 300.50
16 14.22 227.50
32
DM
Ya
Tidak
Total
CIMT
N Mean Rank Sum of Ranks
Test Statisticsb
91.500
227.500
-1.376
.169
.171a
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
Exact Sig. [2*(1-tailed
Sig.)]
CIMT
Not corrected for ties.a.
Grouping Variable: DMb.
93
Usia (Keseluruhan)
Explore Tests of Normality
Usia
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT 20-39 .308 5 .136 .834 5 .148
40-49 .325 8 .013 .810 8 .036
50-59 .153 19 .200* .872 19 .016
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
NPar Tests Kruskal-Wallis Test
Obesitas (Keseluruhan)
Explore Tests of Normality
Obesitas
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT Ya .166 17 .200* .872 17 .024
Tidak .166 15 .200* .911 15 .141
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
94
NPar Tests Mann-Whitney Test
Ranks
Obesitas N
Mean
Rank
Sum of
Ranks
CIMT Ya 17 18.65 317.00
Tidak 15 14.07 211.00
Total 32
Dislipidemi (Keseluruhan)
Explore
Tests of Normality
Dislipidemia
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT Ya .149 22 .200* .865 22 .006
Tidak .150 10 .200* .931 10 .454
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
95
NPar Tests Mann-Whitney Test
Ranks
Dislipidemia N
Mean
Rank
Sum of
Ranks
CIMT Ya 22 19.30 424.50
Tidak 10 10.35 103.50
Total 32
Tingkat aktivitas fisik (Keseluruhan)
Explore Tests of Normality
Tingkat aktivitas fisik
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT Rendah .186 21 .055 .826 21 .002
Sedang .165 8 .200* .965 8 .856
Tinggi .290 3 . .926 3 .475
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
96
NPar Tests Kruskal-Wallis Test
Riwayat merokok (Keseluruhan)
Explore Tests of Normality
Riwayat merokok
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CIMT Ya .196 13 .182 .879 13 .069
Tidak .165 19 .189 .898 19 .045
a. Lilliefors Significance Correction
97
NPar Tests Mann-Whitney Test
Ranks
Riwayat
merokok N
Mean
Rank
Sum of
Ranks
CIMT Ya 13 18.00 234.00
Tidak 19 15.47 294.00
Total 32
98
Lampiran 8. Dokumentasi Penelitian
Penjelasan penelitian dan wawancara oleh penulis
Pengambilan data CIMT
99
Lampiran 9.
BIODATA MAHASISWA
Identitas
Nama : Mutiara Chairsabella
NIM : 22010112130070
Tempat/Tanggal Lahir: Semarang, 5 September 1994
Jenis Kelamin : Perempuan
Alamat : Jl. Wamena Raya D.194/195 Beji, Ungaran
No. Handphone : 081321347312
Email : [email protected]
Riwayat Pendidikan Formal
1. SD : SDIT Assalamah Ungaran Lulus tahun: 2006
2. SMP : SMP Semesta Semarang Lulus tahun: 2009
3. SMA : SMA Semesta Semarang Lulus tahun: 2012
4. S1 : Fakultas Kedokteran Universitas Diponegoro Masuk tahun: 2012
Keanggotaan Organisasi
1. Bidang Hubungan Luar HIMA KU Undip tahun 2013 s/d 2014
2. AMSA Undip tahun 2013 s/d 2014
Publikasi Ilmiah
1. Mutiara Chairsabella, Valensa Yosephi, Yustina Wahyuningtiyas, Kis
Djamiatun. Vaksin Vektor Virus Penguat BCG Sebagai Upaya Eliminasi
Tuberkulosis (TB). JIMKI, 2016, Volume 4, Nomor 1, Halaman 24-34
Prestasi
1. Medali perunggu SIMPIC Faculty of Medicine Mahidol University 2015
2. Medali perunggu II AVSQ AMSW FK Unair 2015